ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibrosis"

  • Abstract Number: 2704 • 2016 ACR/ARHP Annual Meeting

    Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Psoriasis

    Vishal Deshmukh1, Melinda Pedraza1, Maureen Ibanez1, Luis Dellamary1, Josh Stewart1, Timothy Seo1, Benoit Melchior1, John Hood2 and Yusuf Yazici1, 1Samumed, LLC, San Diego, CA, 2Samumed, LLC (formerly), San Diego, CA

    Background/Purpose: Psoriasis is an auto-immune disease of the skin, characterized by inflammation and fibrosis producing patches of red, itchy and scaly skin. Wnt signaling plays…
  • Abstract Number: 1926 • 2015 ACR/ARHP Annual Meeting

    Wnt5a Activates Wnt/PCP-Signaling to Promote Fibroblast Activation and Fibrosis

    Chih-Wei Chen1, Neng-Yu Lin1, Yun Zhang1, Jingang Huang1, Katrin Palumbo-Zerr1, Alexandra Schambony2, Christian Beyer1, Georg Schett1 and Jeorg HW Distler1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Biology, Development Biology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: While canonical Wnt/beta-catenin signaling has been identified as a core pathway of fibrosis in SSc, non-canonical Wnt signaling pathways have not yet been analyzed.…
  • Abstract Number: 1927 • 2015 ACR/ARHP Annual Meeting

    Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc

    Peter J. Wermuth1 and Sergio A. Jimenez2, 1Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, 2Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Activated myofibroblasts are the primary mediators of the excessive synthesis and deposition of collagens and other extracellular matrix (ECM) macromolecules during the pathogenesis of…
  • Abstract Number: 2150 • 2015 ACR/ARHP Annual Meeting

    Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis

    Matthieu Ponsoye1, Camelia Frantz2, Nadira Ruzehaji3, Muriel Elhai4, Barbara Ruiz1, Anne Cauvet1, Yannick Allanore5 and Jerome Avouac4, 1INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3INSERM U1016, Paris Descartes University, Paris, France, 4Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 5Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France

    Background/Purpose: Early stages of systemic sclerosis (SSc) are characterized by inflammatory skin infiltrates mainly composed of activated T cells. Cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) is…
  • Abstract Number: 2152 • 2015 ACR/ARHP Annual Meeting

    Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases

    Elena Pachera1, Shervin Assassi2, Gloria Salazar2, Mojca Frank Bertoncelj3, Rucsandra Dobrota4, Matthias Brock5, Serena Vettori6, Claus Hellerbrand7, Carol A. Feghali-Bostwick8, Jeorg HW Distler9, Gabriela Kania10 and Oliver Distler11, 1Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, Schileren, Switzerland, 2Rheumatology, University of Texas Medical School at Houston, Houston, TX, 3Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland, 4Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Department of Pulmonology, University Hospital Zurich, Schileren, Switzerland, 6Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, 7Department of Internal Medicine I, University of Regensburg, Regensburg, Germany, 8Medicine, University of Pittsburgh, Pittsburgh, PA, 9Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 10Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, 11Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland

    Background/Purpose: Long noncoding RNAs (LncRNAs) are emerging as a novel class of noncoding transcripts involved in the regulation of gene expression. So far, for only…
  • Abstract Number: 2154 • 2015 ACR/ARHP Annual Meeting

    Inhibition of Gli Ameliorates the Pro-Fibrotic Effects of Transforming Growth Factor-β in Systemic Sclerosis

    Ruifang Liang1, Clara Dees2, Katrin Palumbo-Zerr3, Yun Zhang3, Oliver Distler4, Georg Schett3 and Jeorg HW Distler3, 1Rheumatology and Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland

    Background/Purpose: Hedgehog signaling plays a critical role in the pathogenesis of fibrosis in Systemic sclerosis (SSc). Besides canonical hedgehog signaling with Smoothened (Smo)-dependent activation of…
  • Abstract Number: 2155 • 2015 ACR/ARHP Annual Meeting

    Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma

    Ilia Atanelishvili1, Yuichiro Shirai2, Tanjina Akter3, Erik Stolarzewicz4, Rolf E Swenson5, Richard Silver6 and Galina S. Bogatkevich7, 1Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, 2Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 3Medical University of South Carolina, charleston, SC, 4Chem-Master International Inc, Stony Brook, NY, 5Arroyo BioSciences, Silver Spring, MD, 6Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 7Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Activation of sphingosine-1-phosphate (S1P) signaling has been extensively documented in various fibrotic conditions including pulmonary fibrosis. The aim of this study was to provide…
  • Abstract Number: 190 • 2015 ACR/ARHP Annual Meeting

    Ultrasound Imaging with Elastography for the Medical Treatment of Dupuytren’s Contracture

    Paul John DeMarco1, Alan K. Matsumoto1, Nicole Thomas2, Megan Bishop1, Andrew Gregory DeMarco3, Guada Respicio1, Ashley Beall1, Robert Rosenberg1, Theresa Bass-Goldman1 and Herbert S. B. Baraf1, 1The Center for Rheumatology and Bone Research, Wheaton, MD, 2Rheumatology, Georgetown University Hospital, Washington DC, DC, 3Duquesne University, Pittsburgh, PA

    Background/Purpose:  Dupuytren’s contracture is a rheumatic disease characterized by an fibrotic reaction in the palmar aponeurosis, resulting in disability.  Medical treatment with up to 3…
  • Abstract Number: 2984 • 2015 ACR/ARHP Annual Meeting

    Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity:  Correlation with Pulmonary Function

    Merrideth Ashley Morris1, Tanjina Akter2, Paul Nietert3, Galina S. Bogatkevich2 and Richard Silver4, 1Medical University of South Carolina, Charleston, SC, 2Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 3Division of Public Health Science, Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Multiple lines of evidence identify thrombin as an important mediator of lung fibrosis in systemic sclerosis (SSc).  In addition to demonstrating dramatically high levels…
  • Abstract Number: 832 • 2015 ACR/ARHP Annual Meeting

    The Validity and Reliability of Online Obituaries As a Source of Mortality Data

    Medha Soowamber1, John T. Granton2, Fatemeh Bavaghar-Zaeimi3 and Sindhu R. Johnson4,5, 1Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, 2Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, 3Rheumatology, Toronto Scleroderma Program, Toronto Western Hospital and Mount Sinai Hospital, Toronto, ON, Canada, 4Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 5Institute of Health Policy, Management and Evaluation,, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Loss to follow-up is a major threat to the conduct of chronic disease cohort research. Tracking the survival status of patients who are lost…
  • Abstract Number: 3000 • 2015 ACR/ARHP Annual Meeting

    Intrinsic Gene Expression Subset Predicts Improvement in Systemic Sclerosis Patients during Dasatinib (SprycelTM) Therapy

    Viktor Martyanov1, Jonathan Goldin2, Kim Hyun3, Oumar Sy4, Wendy Hayes4, Shuyan Du4, Michael Whitfield1 and John Varga5, 1Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 2David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 3Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 4Bristol-Myers Squibb, Princeton, NJ, 5Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Intrinsic gene expression subsets are molecular pathway-driven subtypes of systemic sclerosis (SSc) that have been reproduced across multiple cohorts of SSc patients. The goal…
  • Abstract Number: 1365 • 2015 ACR/ARHP Annual Meeting

    Innate Lymphoid Cells. New Players in Systemic Sclerosis Correlate with Extent of Skin and Lung Fibrosis

    Thomas Wohlfahrt1, Stefanie Weber1, Matthias Englbrecht2, Clara Dees3, Christian Beyer3, Oliver Distler4, Georg Schett1, Jorg HW Distler1,3 and Andreas Ramming1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 4Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Type 2 innate lymphoid cells (ILC2s), are recently identified as population of cells with lymphoid morphology lacking re-arranged antigen-specific receptors. Although findings in animal…
  • Abstract Number: 3008 • 2015 ACR/ARHP Annual Meeting

    Role of PTP4A1 Tyrosine Phosphatase in Systemic Sclerosis

    Cristiano Sacchetti1, Stephanie Stanford2, Yunpeng Bai3, Zhong-Yin Zhang4, Amin Gholami5, Gregory Seumois6, Maria Piera-Velazquez7, Sergio A. Jimenez8 and Nunzio Bottini1, 1Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3Indiana University, School of Medicine, Indianapolis, IN, 4Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 5Bioinformatics Core, La Jolla Institute for Allergy and immunology, La Jolla, CA, 6Sequencing Facility, La Jolla Institute for Allergy and immunology, La Jolla, CA, 7Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, PA, 8Div Connective Tissue Diseases, Thomas Jefferson Univ, Philadelphia, PA

    Background/Purpose: Systemic sclerosis (SSc) is a multi-system autoimmune connective tissue disorder that leads to fibrosis of the skin and internal organs, resulting in significant patient…
  • Abstract Number: 1886 • 2015 ACR/ARHP Annual Meeting

    Myocardial Fibrosis Detected By Magnetic Resonance Imaging Is a Predictor of Heart Failure in Systemic Sclerosis (SSc) Patients

    Tatiana Sofia Rodriguez-Reyna1, Martha Morelos-Guzmán2, Pamela Mercado Velazquez3, Pablo Henrandez-Reyes4, Karla Montero-Duarte5, Cynthia Martinez-Reyes6, Carlos Reyes-Utrera6 and Carlos Nunez Alvarez3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, 4Department of Cardiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 5Department of Imaging and Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 6Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Background/Purpose: In previous studies we showed that prevalence of myocardial fibrosis in SSc patients is 45% and is associated to diffuse disease (dcSSc) and lower…
  • Abstract Number: 3010 • 2015 ACR/ARHP Annual Meeting

    Estrogens Inhibit the Profibrotic Effects of Transforming Growth Factor-Beta and Protect from the Development of Experimental Dermal Fibrosis

    Jerome Avouac1, Léa Baudoin2, Anne Cauvet2, Barbara Ruiz2 and Yannick Allanore3, 1Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 2INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, 3Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France

    Background/Purpose: Systemic sclerosis (SSc) primarily affects postmenopausal women. This sex bias could partly be explained by the action of estrogens on the immune system and/or…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology